Too Big To Fail: What’s Next for the Federal Drug Pricing Program?
Studio BThis session features the ADAP Advocacy Association's 340B Patient Advisory Committee convening its first meeting of the year, featuring Dr. Rory Martin of IQVIA sharing his perspectives on the 340B Drug Pricing Program. The 340B Program has increasingly been targeted for reform by lawmakers at the federal and state levels, and by the Trump Administration's push to move the program to a rebate payment model. The 340B Patient Advisory Committee will convene its next meeting during SYNC to discuss ongoing executive orders, administrative rules, legislation, and pending litigation in numerous federal district courts and appellate courts.

